The predictors of complications in patients with drug-induced liver injury caused by antimicrobial agents
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Issue Date
2010-06
Metadata
Show full item recordCitation
Aliment. Pharmacol. Ther. 2010, 31(11):1200-7Abstract
BACKGROUND: Antimicrobials are the leading cause of idiosyncratic drug-induced liver injury in most series. AIM: To determine the incidence and the predictors of complications in patients with drug-induced liver injury caused by antimicrobial agents requiring hospitalization. METHODS: Medical records of patients with drug-induced liver injury caused by antimicrobial agents were identified by ICD-10, for the period between 2002 and 2006. Clinical information and blood tests during hospitalization were recorded. The causality assessment of drug-induced liver injury was determined by the Roussel UCLAF causality assessment method (RUCAM) scale. RESULTS: Of 47 594 in-patient admissions per year, the annual incidence of drug-induced liver injury was 0.03%. Male: female ratio was 7:3 with a median age of 47 years. Eighty reactions of drug-induced liver injury were caused by anti-tuberculosis drugs (85%) and by antibiotics (15%). The median (IQR) of RUCAM scale was 6 (5-8). A total of 36% had HIV infection and 9% of patients had diabetes mellitus. Median (IQR) duration of hospitalization was 9 (5-15) days. Serious complications and death were found in 27.5% and 26%, respectively. By a multivariable logistic analysis, the presence of jaundice was found to be significantly associated with an unfavourable outcome. CONCLUSION: Although rare, antimicrobial agents-related drug-induced liver injury requiring hospitalization has a high mortality rate. The presence of jaundice predicts poor outcome.Description
To access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldAdditional Links
http://dx.doi.org/10.1111/j.1365-2036.2010.04292.xae974a485f413a2113503eed53cd6c53
10.1111/j.1365-2036.2010.04292.x
Scopus Count
Collections
Related articles
- Drug Induced Liver Injury at a Tertiary Hospital in India: Etiology, Clinical Features and Predictors of Mortality.
- Authors: Rathi C, Pipaliya N, Patel R, Ingle M, Phadke A, Sawant P
- Issue date: 2017 May - Jun
- Epidemiology of drug-induced liver injury in a University Hospital from Colombia: Updated RUCAM being used for prospective causality assessment.
- Authors: Cano-Paniagua A, Amariles P, Angulo N, Restrepo-Garay M
- Issue date: 2019 May - Jun
- Drug-induced liver injury: A 2-year retrospective study of 1169 hospitalized patients in a single medical center.
- Authors: Woo HJ, Kim HY, Choi ES, Cho YH, Kim Y, Lee JH, Jang E
- Issue date: 2015 Dec 1
- Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?
- Authors: Teschke R, Schulze J, Eickhoff A, Danan G
- Issue date: 2017 Apr 11
- Montelukast induced acute hepatocellular liver injury.
- Authors: Harugeri A, Parthasarathi G, Sharma J, D'Souza GA, Ramesh M
- Issue date: 2009 Apr-Jun